Evotec Enters into Integrated Drug Discovery Alliance with Genentech

11-May-2010 - Germany

Evotec AG announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group, to discover novel small molecule therapeutics.

Evotec will apply its integrated and innovative drug discovery platform in combination with its extensive disease biology expertise against targets nominated by Genentech. This will include assay development and high throughput screening, medicinal chemistry and structural biology. The aim of the collaboration is to deliver high quality leads and development candidates to support Genentech’s research efforts.

Further commercial details were not released.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances